

When prescribing Pomalidomide SPC® (Pomalidomide), I agree to:

- Provide patient counseling on the benefits and risks Pomalidomide SPC[®] therapy, including Boxed Warnings.
- Submit a completed Pomalidomide SPC[®] (Pomalidomide) treatment Initiation Form for each new patient.
- Provide contraception and emergency contraception counseling with each new prescription prior to and during **Pomalidomide SPC**[®] treatment.
- Provide scheduled pregnancy testing for females of reproductive potential and verify negative pregnancy test results prior to writing a new prescription or subsequent prescriptions.
- Report any pregnancies in female patients or female partners of male patients prescribed **Pomalidomide SPC**[®] immediately to Sudair Pharma Pharmacovigilance Department.
- Prescribe no more than a 4-week (28-day) supply, with no automatic refills or telephone prescriptions.
- Remind patients to return all Pomalidomide SPC[®] capsules to Sudair Pharma Head Office or their Pomalidomide SPC[®] prescriber, or to the pharmacy that dispensed the Pomalidomide SPC[®] to them.
- Re-enroll patients in the Pomalidomide SPC[®] program if Pomalidomide SPC[®] is required and previous therapy with Pomalidomide SPC[®] has been discontinued for 12 consecutive months.



This document has been reviewed and approved by The Saudi Food and Drug Authority (SFDA). Version: 1.0 | Date: December 2022

Please fill out the spaces below completely.

Pomalidomide SPC[®] Prescriber Registration Form

Prescriber Name:				
Degree: MD / DO / PA / NP / Fellow / Medical Resident				
Specialty:				
Please indicate which office(s) will receive Pomalidomide SPC® materials and updates:				
Hospital Name:				
Department:				
Address:	. City:			
Phone:	_ Ext:	Fax:		
Email Address:				

I understand that if I fail to comply with all requirements of the Lenalidomide SPC® program, my prescriptions for **Pomalidomide SPC**[®] (Pomalidomide) will not be honored at certified pharmacies.

Prescriber Signature:	Date:
SPC سدير للأدوية	Mail to: Riyadh Gallery Mall, Building A2, Office 305-A, Riyadh, Saudi Arabia Phone: 920001432, ext. 107 Fax: 00966 11 4668195 Email: Pharmacovigilance@SudairPharma.com
	www.SudairPharma.com
	This document has been reviewed and approved by The Saudi Food and Drug Authority (SFDA). Version: 1.0 Date: December 2022
	page 2 of 2